SNGX

Soligenix Inc.

SNGX, USA

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

https://www.soligenix.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SNGX
stock
SNGX

moha gov vn> 2025> Swing Trade: Why SNGX stock appeals to analysts - IPO Watch & AI Based Trade Execution Alerts moha.gov.vn

Read more →
SNGX
stock
SNGX

EPS Watch: Will AGMPRE stock outperform growth indexes - July 2025 Breakouts & Growth Focused Stock Reports moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$17.5

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.94

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-33.31 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-22.41 %

Low 2%

High 10%

Debt to Equity

-

High

0.49

Low 1

High 0.3

Investors

* Institutions hold a combined 5.29% of the total shares of Soligenix Inc.

1.

Connective Capital Management LLC

(2.788%)

since

2025/06/30

2.

Geode Capital Management, LLC

(0.6968%)

since

2025/06/30

3.

UBS Group AG

(0.4532%)

since

2025/06/30

4.

Citadel Advisors Llc

(0.3537%)

since

2025/06/30

5.

Fidelity Extended Market Index

(0.3346%)

since

2025/07/31

6.

Fidelity Total Market Index

(0.1879%)

since

2025/07/31

7.

Morgan Stanley - Brokerage Accounts

(0.089%)

since

2025/06/30

8.

Spartan Extended Market Index Pool F

(0.0816%)

since

2025/07/31

9.

Fidelity Series Total Market Index

(0.0811%)

since

2025/07/31

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.051%)

since

2025/07/31

11.

Northern Trust Extended Eq Market Idx

(0.041%)

since

2025/06/30

12.

NT Ext Equity Mkt Idx Fd - L

(0.041%)

since

2025/06/30

13.

Tower Research Capital LLC

(0.0324%)

since

2025/06/30

14.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0116%)

since

2025/06/30

15.

Spartan Total Market Index Pool G

(0.0115%)

since

2025/07/31

16.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0098%)

since

2024/12/31

17.

Plante Moran Financial Advisors LP

(0.007%)

since

2025/06/30

18.

Royal Bank of Canada

(0.0058%)

since

2025/06/30

19.

State St US Extended Mkt Indx NL Cl C

(0.0044%)

since

2025/08/31

20.

NT Ext Equity Mkt Idx Fd - NL

(0.0021%)

since

2025/06/30

21.

BNYM Mellon SL Market Completion UC1

(0.0018%)

since

2025/06/30

22.

SSgA U.S. Total Market Index Strategy

(0.0018%)

since

2025/03/31

23.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0016%)

since

2025/06/30

24.

Bank of America Corp

(0.0007%)

since

2025/06/30

25.

JONES FINANCIAL COMPANIES LLLP

(0.0006%)

since

2025/06/30

26.

State St US Ttl Mkt Indx NL Cl A

(0.0005%)

since

2025/08/31

27.

Northern Trust Wilshire 5000

(0.0003%)

since

2025/06/30

28.

CWM, LLC duplicate

(0.0001%)

since

2025/06/30

29.

BNYM Mellon NSL Mkt Completion Fund Inst

(0.0001%)

since

2025/06/30

30.

Albion Financial Group (Utah)

(0%)

since

2025/06/30

31.

SBI Securities Co Ltd

(0%)

since

2025/06/30

32.

Advisor Group Holdings, Inc.

(0%)

since

2025/06/30

33.

NT Quality SCC US Fund - L

(0%)

since

2025/06/30

34.

NT Quality Small Cap Core

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.58

EPS Estimate

-0.48

EPS Difference

-0.1

Surprise Percent

-20.8333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.